The TALAPRO-3 clinical trial studied a combination therapy that includes enzalutamide, a medication that blocks male hormones from fueling cancer growth, and the drug talazoparib in patients with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for TALZENNA® (talazoparib) in Combination with XTANDI® (enzalutamide) to Identify Patients with HRR ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib to ...

The talazoparib treatment regimen demonstrated a significant improvement in rPFS vs placebo plus enzalutamide, exceeding the pre-specified target hazard ratio of 0.63. Topline data were announced from ...

TALAPRO-3 demonstrated clinically meaningful rPFS improvement for talazoparib plus enzalutamide over enzalutamide alone in HRR-mutated mCSPC, exceeding the prespecified hazard ratio target. Efficacy ...

With athletes from all around the world competing at the 2026 Winter Olympics, pronouncing their names can get a little tricky at times. Luckily, the official Olympics website has a handy way to help ...

The National Institute for Health and Care Excellence (NICE) has recommended a new oral treatment for men with untreated hormone-relapsed metastatic prostate cancer. NICE assessed evidence from the ...

Oregon toponyms, or place names, often originate from Native American languages, reflecting the region's history and culture. Correct pronunciation distinguishes locals from newcomers, with variations ...

An analysis of a phase III trial presented at this year's American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium showed that adding the PARP inhibitor talazoparib (Talzenna) to ...

SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate cancer (CRPC) prolonged survival, new analyses from the ...